+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Biosimilars in the US Oncology Market (2nd Edition)

  • ID: 4226994
  • Report
  • Region: Global, United States
  • 31 Pages
  • Industry Standard Research (ISR)
1 of 2

This report provides data and insights from 101 US-based, board-certified oncologists or hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology.

Use the data contained in this report to better understand how US-based oncologists will make prescribing decisions in a marketplace that includes biosimilar oncology options and how this has changed since 2012.

What You Will Learn:

  • Familiarity with biosimilars
  • Expected pricing/discount levels
  • Preferred primary endpoints
  • Influence the manufacturer plays in the prescribing decision
  • How the data have changed since 2012

How You Can Use This Report:

  • Use this report to inform your market access strategies, reimbursement plans, and manufacturing capacity planning.
  • Better inform your sales and marketing efforts by understanding the benefits and barriers physicians see in prescribing biosimilars.
Note: Product cover images may vary from those shown
2 of 2

1. Introduction

2. Methodology

3. Statistical Significance

4. Respondent Qualifications

  • Practice area
  • Years in practice
  • Types of cancer treated
  • Primary practice setting

5. Summary Findings 

  • Awareness of Biosimilars among US Oncologists
  • Data Points/Evidence for Evaluating Biosimilars
  • Manufacturer of Biosimilars
  • Potential Benefit of Biosimilars to Practices and to Patients
  • Pricing, Prescribing and Reimbursement

6. Study Data

  • Familiarity with Biosimilars
    • Statistical differences
  • Concern for safety and efficacy
  • Biosimilar pricing level-discount expectations
  • Preferred primary endpoints for biosimilars
    • Statistical differences
  • Reimbursement policies when Biosimilars are available
    • Statistical differences
  • Influence of Biosimilar manufacturer on prescribing decision
  • Data/evidence needed for evaluating a biosimilar product
  • Perception of potential benefits of biosimilars to practice
  • Perception of potential benefits of biosimilars to patients
  • Summary
Note: Product cover images may vary from those shown
3 of 2